Candriam S.C.A. Atreca, Inc. Transaction History

Candriam S.C.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$4.91 - $9.07 $1.83 Million - $3.39 Million	-373,706 Closed	0 $0
Q2 2021 Jul 20, 2021	BUY	$7.82 - $13.8 $2.92 Million - $5.16 Million	373,681 Added 1494724.0%	373,706 $3.18 Million
Q1 2021 Apr 29, 2021	BUY	$13.0 - $19.34 $325 - $483	25 New	25 $0

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.